Intense violet–blue emission and paramagnetism of nanocrystalline Gd3+ doped ZnO ceramics

Nanocrystalline Zn1-xGdxO (x = 0, 0.02, 0.04, 0.06, and 0.08) ceramics were synthesized by ball milling and subsequent solid-state reaction. The transmission electron microscopy (TEM) micrograph of as synthesized samples revealed the formation of crystallites with an average diameter of 60 nm, and the selected area electron diffraction (SAED) pattern confirmed the formation of wurtzite structure. A red shift in the band gap was observed with increasing Gd3+ concentration. The photoluminescence of nanocrystalline Gd3+ doped ZnO exhibited a strong violet–blue emission. Concentration dependence of the emission intensity of Gd3+ in ZnO was studied, and the critical concentration was found to be 4 mol% of Gd3+. The Gd3+ doped ZnO exhibited paramagnetic behavior at room temperature, and the magnetic moment increased with Gd3+ concentration

Dynamic stability of a nonlinear multiple-nanobeam system

We use the incremental harmonic balance (IHB) method to analyse the dynamic stability problem of a nonlinear multiple-nanobeam system (MNBS) within the framework of Eringen’s nonlocal elasticity theory. The nonlinear dynamic system under consideration includes MNBS embedded in a viscoelastic medium as clamped chain system, where every nanobeam in the system is subjected to time-dependent axial loads. By assuming the von Karman type of geometric nonlinearity, a system of m nonlinear partial differential equations of motion is derived based on the Euler–Bernoulli beam theory and D’ Alembert’s principle. All nanobeams in MNBS are considered with simply supported boundary conditions. Semi-analytical solutions for time response functions of the nonlinear MNBS are obtained by using the single-mode Galerkin discretization and IHB method, which are then validated by using the numerical integration method. Moreover, Floquet theory is employed to determine the stability of obtained periodic solutions for different configurations of the nonlinear MNBS. Using the IHB method, we obtain an incremental relationship with the frequency and amplitude of time-varying axial load, which defines stability boundaries. Numerical examples show the effects of different physical and material parameters such as the nonlocal parameter, stiffness of viscoelastic medium and number of nanobeams on Floquet multipliers, instability regions and nonlinear amplitude–frequency response curves of MNBS. The presented results can be useful as a first step in the study and design of complex micro/nanoelectromechanical systems

Prenatal Excess Glucocorticoid Exposure and Adult Affective Disorders:A Role for Serotonergic and Catecholamine Pathways

Fetal glucocorticoid exposure is a key mechanism proposed to underlie prenatal ‘programming’ of adult affective behaviours such as depression and anxiety. Indeed, the glucocorticoid metabolising enzyme 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2), which is highly expressed in the placenta and the developing fetus, acts as a protective barrier from the high maternal glucocorticoids which may alter developmental trajectories. The programmed changes resulting from maternal stress or bypass or from the inhibition of 11β-HSD2 are frequently associated with alterations in the hypothalamic-pituitary-adrenal (HPA) axis. Hence, circulating glucocorticoid levels are increased either basally or in response to stress accompanied by CNS region-specific modulations in the expression of both corticosteroid receptors (mineralocorticoid and glucocorticoid receptors). Furthermore, early-life glucocorticoid exposure also affects serotonergic and catecholamine pathways within the brain, with changes in both associated neurotransmitters and receptors. Indeed, global removal of 11β-HSD2, an enzyme that inactivates glucocorticoids, increases anxiety‐ and depressive-like behaviour in mice; however, in this case the phenotype is not accompanied by overt perturbation in the HPA axis but, intriguingly, alterations in serotonergic and catecholamine pathways are maintained in this programming model. This review addresses one of the potential adverse effects of glucocorticoid overexposure in utero, i.e. increased incidence of affective behaviours, and the mechanisms underlying these behaviours including alteration of the HPA axis and serotonergic and catecholamine pathways

Vibration analysis of viscoelastic single-walled carbon nanotubes resting on a viscoelastic foundation

Vibration responses were investigated for a viscoelastic Single-walled carbon nanotube (visco-SWCNT) resting on a viscoelastic foundation. Based on the nonlocal Euler-Bernoulli beam model, velocity-dependent external damping and Kelvin viscoelastic foundation model, the governing equations were derived. The Transfer function method (TFM) was then used to compute the natural frequencies for general boundary conditions and foundations. In particular, the exact analytical expressions of both complex natural frequencies and critical viscoelastic parameters were obtained for the Kelvin-Voigt visco-SWCNTs with full foundations and certain boundary conditions, and several physically intuitive special cases were discussed. Substantial nonlocal effects, the influence of geometric and physical parameters of the SWCNT and the viscoelastic foundation were observed for the natural frequencies of the supported SWCNTs. The study demonstrates the efficiency and robustness of the developed model for the vibration of the visco-SWCNT-viscoelastic foundation coupling system

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .)